A fixed rule set over this filing's XBRL figures and the number of high-severity risks found in it — no model judgement.
Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →
AI Takeaway
In 2026-Q2, GE HealthCare reported total revenues of $5.295B (up 5.8% YoY) and net income of $561M ($1.24 diluted EPS), driven by strong demand in its newly formed Advanced Imaging Solutions segment and the strategic acquisition of Intelerad.
Filed · Source: SEC EDGAR 10-Q filing
GE HealthCare delivered solid 2026-Q2 results with revenue rising 5.8% YoY to $5.295B and diluted EPS expanding 17.0% to $1.24 amid segment streamlining and software acquisition growth.
Last 4 quarters: 2 beats, 2 misses
In 2026-Q2, GE HealthCare combined its Imaging and Advanced Visualization Solutions businesses into a new reportable segment named Advanced Imaging Solutions (AIS), bringing its reportable segments to three: AIS, Pharmaceutical Diagnostics (PDx), and Patient Care Solutions (PCS).
Source: 10-Q Item 2 MD&A, Note 3, p.10
On March 18, 2026, the company acquired 100% of Intelerad for approximately $2.293B in cash to expand its medical imaging software and digital enterprise workflow capabilities within the AIS segment.
Source: 10-Q Item 2 MD&A, Note 7, p.15
Total revenues for 2026-Q2 reached $5.295B, up 5.8% from $5.007B in 2025-Q2. Net income attributable to GE HealthCare grew 15.4% YoY to $561M, while diluted EPS increased 17.0% to $1.24.
Source: 10-Q Item 2 MD&A, Condensed Consolidated Statements of Income, p.4
Total remaining performance obligations stood at $16.118B as of June 30, 2026 (comprising $5.180B in products and $10.939B in services), up from $15.729B at year-end 2025.
Source: 10-Q Item 2 MD&A, Note 2, p.11
GE HealthCare carried $10.091B in long-term debt as of June 30, 2026, compared to $2.105B in cash and cash equivalents. High leverage increases financial obligations and interest charges, which totaled $114M in 2026-Q2.
Source: 10-Q Condensed Consolidated Statements of Financial Position, p.6
The company deployed $2.293B in cash for the acquisition of Intelerad during 1H 2026. Failure to effectively integrate acquired technology or achieve projected synergies could impact future profitability.
Source: 10-Q Condensed Consolidated Statements of Cash Flows, p.9
Fluctuations in foreign exchange rates resulted in a $71M currency translation loss in 2026-Q2, compared to a $221M gain in 2025-Q2, creating volatility in accumulated other comprehensive income.
Source: 10-Q Condensed Consolidated Statements of Comprehensive Income, p.5
This analysis does not extract a guidance section. Companies issue revenue and EPS outlook in the 8-K press release and on the earnings call rather than in the 10-Q itself — though the filing's management discussion can contain forward-looking statements, which appear in the highlights above where they were material.
See the GEHC earnings preview — expected date, analyst estimates and what to watch →
GE HealthCare generated $5.295B in revenue for 2026-Q2, up 5.8% YoY from $5.007B. Net income attributable to the company grew 15.4% YoY to $561M, resulting in diluted EPS of $1.24 compared to $1.06 in 2025-Q2.
The newly formed Advanced Imaging Solutions (AIS) segment produced $3.771B in revenue and $525M in Segment EBIT. Pharmaceutical Diagnostics (PDx) recorded $843M in revenue and $250M in EBIT, while Patient Care Solutions (PCS) reported $675M in revenue and $(26)M in EBIT.
GE HealthCare highlighted the acquisition of Intelerad, completed on March 18, 2026, for $2.293B in cash. The business expands GEHC's medical imaging software and enterprise workflow offerings within the AIS segment.
As of June 30, 2026, GE HealthCare reported total remaining performance obligations of $16.118B. This consists of $5.180B in product backlog and $10.939B in service contracts.
Expected release date, analyst estimates & what to watch
GE HealthCare reported Q1 2026 revenue of $5.13B (+7.4% YoY), but profitability deteriorated sharply with net income falling 31% to $389M, driven by gross margin compression of ~360 bps and a surge in investing cash outflows reflecting significant acquisition activity.
GE HealthCare (GEHC) delivered solid FY2025 results with revenue growing 4.8% to $20.6B and net income rising 4.6% to $2.1B, though gross margin compressed 170 basis points to 40.0% amid ongoing cost pressures.
Other companies in Health Care Equipment